Differences in the Approach to Guideline-Directed Medical Therapy in Patients with Heart Failure with Reduced

Lana Alhashimi1, David J Cordwin1, Jessica Guidi2,3

  • 1College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.

Insights

Pharmacists are more likely to adjust guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF) than physicians. This study highlights their key role in optimizing GDMT prescribing for better patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Guideline-directed medical therapy (GDMT) significantly improves outcomes in patients with heart failure with reduced ejection fraction (HFrEF).
  • Suboptimal prescribing of GDMT remains a challenge in clinical practice.
  • Understanding prescribing patterns among different healthcare professionals is crucial for improving GDMT implementation.

Purpose of the Study:

  • To survey cardiologists, internists, and pharmacists regarding their approach to GDMT prescribing in HFrEF.
  • To compare the GDMT prescribing behaviors of pharmacists versus physicians (cardiologists and internists).

Main Methods:

  • A survey with 20 clinical vignettes of HFrEF patients was administered to 127 cardiologists, 68 internists, and 89 pharmacists.
  • Responses regarding GDMT adjustments were collected and dichotomized.
  • A mixed-effect model was used to analyze the odds of changing GDMT between pharmacists and physicians.

Main Results:

  • Pharmacists were more likely than internists to make GDMT changes (92.1% vs 82%; OR 3.02).
  • Pharmacists demonstrated higher likelihoods in initiating beta-blockers and mineralocorticoid receptor antagonists compared to physicians.
  • Pharmacists showed greater propensity than physicians to titrate beta-blockers and angiotensin receptor-neprilysin inhibitors (ARNI).

Conclusions:

  • Pharmacists exhibit a higher likelihood of making GDMT adjustments for HFrEF compared to internists and cardiologists.
  • Pharmacists' prescribing preferences include initiating spironolactone and titrating beta-blockers.
  • Pharmacists are more likely than internists to initiate beta-blockers and titrate ARNI, suggesting a distinct role in HFrEF management.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
350
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
543
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
68